These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11603275)

  • 1. [Value of Synercid in clinical practice: from temporary approval to clinical trial authorization].
    Potel G
    Presse Med; 2001 Sep; 30(25 Pt 2):XIX-XXII. PubMed ID: 11603275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
    Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental models: interaction of Synercid with other anti-Gram positive agents].
    Fantin B
    Presse Med; 2001 Sep; 30(25 Pt 2):XV-XVIII. PubMed ID: 11603276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two new treatment options for infections due to drug-resistant gram-positive cocci.
    Rehm SJ
    Cleve Clin J Med; 2002 May; 69(5):397-401, 405-13. PubMed ID: 12022383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiological context: microbiological value of Synercid].
    Etienne J
    Presse Med; 2001 Sep; 30(25 Pt 2):VI-IX. PubMed ID: 11603273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction of Synercid].
    Régnier B
    Presse Med; 2001 Sep; 30(25 Pt 2):IV. PubMed ID: 11603272
    [No Abstract]   [Full Text] [Related]  

  • 7. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal.
    Johnson AP; Livermore DM
    Lancet; 1999 Dec; 354(9195):2012-3. PubMed ID: 10636359
    [No Abstract]   [Full Text] [Related]  

  • 8. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
    Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
    Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of vancomycin-resistant Enterococcus faecium infections.
    Lai KK
    Arch Intern Med; 1996 Dec 9-23; 156(22):2579-84. PubMed ID: 8951301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.
    Linden PK; Moellering RC; Wood CA; Rehm SJ; Flaherty J; Bompart F; Talbot GH;
    Clin Infect Dis; 2001 Dec; 33(11):1816-23. PubMed ID: 11668430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental models: interactions Synercid and beta-lactam antibiotics].
    Moreillon P
    Presse Med; 2001 Sep; 30(25 Pt 2):X-XIV. PubMed ID: 11603274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
    Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
    J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for gram-positive nosocomial sepsis.
    Wood MJ
    J Chemother; 1999 Dec; 11(6):446-52. PubMed ID: 10678786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Linezolid versus vancomycin in the treatment of pneumonia caused by Gram-positive cocci: meta-analysis of randomised controlled trials].
    Lin ZQ; Huang YL; Huang P; Chen Q
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Dec; 33(12):900-6. PubMed ID: 21211409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases.
    Sgarabotto D; Cusinato R; Narne E; Scano F; Zignol M; Gambino A; Cattelan A; Meneghetti F; Cadrobbi P
    Scand J Infect Dis; 2002; 34(2):122-6. PubMed ID: 11928842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synercid Aventis.
    Pavan B
    Curr Opin Investig Drugs; 2000 Oct; 1(2):173-80. PubMed ID: 11249570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections.
    Wilson SE
    Surg Infect (Larchmt); 2001; 2(1):25-35. PubMed ID: 12594878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [GEIPC-SEIMC (Study Group for Infections in the Critically Ill Patient of the Spanish Society for Infectious Diseases and Clinical Microbiology) and GTEI-SEMICYUC ( Working Group on Infectious Diseases of the Spanish Society of Intensive Medicine, Critical Care, and Coronary Units) recommendations for antibiotic treatment of gram-positive cocci infections in the critical patient].
    Astigarraga PM; Montero JG; Cerrato SG; Colomo OR; Martínez MP; Crespo RZ; García-Paredes PM; Cerdá EC; Lerma FA
    Enferm Infecc Microbiol Clin; 2007; 25(7):446-66. PubMed ID: 17692213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
    Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
    Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.